Видео с ютуба Dr Landsburg

The real-world outcomes of tisa-cel in patients with aggressive B-cell lymphoma

Evaluating the role of autoSCT in patients with DLBCL who relapse after first-line therapy

The current role of SCT in LBCL in the era of novel therapies: identifying patients who may benefit

The impact of TP53 mutations and copy number loss on survival outcomes in patients with LBCL

Predictors of long-term survival in patients with DLBCL/HGBCL following autoSCT

Prof Steven Landsburg: The problem with taxing capital

Dr. Steven Landsburg Speaks at Hillsdale College

Interview with Professor Steven Landsburg — The Soul of Enterprise: Business in the Knowledge...

Outcomes of patients with DLBCL following ASCT and/or CAR-T

Welcome to arthritisCARE

Peter Lansberg discusses the new IAS Consensus Paper on severe FH

The Unconventional Wisdom of Economics

Diagnosing and managing Lupus

Why you sometimes need to consider medications for managing autoimmune diseases

Making Sense of Economic Reasoning and Incentives | Free to Exchange

CI 157 - Why Central Planning Will Never Work with Steven Landsburg

Ankylosing Spondylitis: How to diagnose and treat it

Rheumatoid Arthritis: What you need to know

POLARIX lymphoma trial debate